Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Neoplasms 2Colorectal Neoplasms 2Liver Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Digestive System Neoplasms 1Desmoid Tumors 1Adrenocortical Carcinoma 1

Interventions

pembrolizumab 15Paclitaxel 15Carboplatin 13Specimen Handling 6Biopsy 6durvalumab 5Magnetic Resonance Spectroscopy 5dostarlimab 4Taxes 4Surveys and Questionnaires 4Observation 4Letrozole 4Everolimus 4Cisplatin 4olaparib 3lenvatinib 3ceralasertib 3Doxorubicin 3sacituzumab govitecan 2pertuzumab 2copanlisib 2cabozantinib 2atezolizumab 2abemaciclib 2Trastuzumab 2Robotic Surgical Procedures 2Pemetrexed 2Nivolumab 2Metformin 2Megestrol Acetate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Endometrial Neoplasms × E-7386 × Clear all
NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Eisai Inc.

Phase 1/2 Active not recruiting
301 enrolled
GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡